Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

Fig. 2

Effect of spontaneous complement activation on PNH red cells. a Kinetics of C3 binding on PNH red cells from a representative PNH patient not on eculizumab after spontaneous complement activation in presence of eculizumab. The first panel shows that no C3 binding is present on red cells from patients not on eculizumab. The second panel shows that there is no C3 binding on red cells after 5 days of incubation at 37 °C in ABO-compatible sera without eculizumab. C3 binding (C3+) appears on PNH (CD59-negative) red cells after 3 (third panel) and after 5 (fourth panel) days of incubation at 37 °C in ABO-compatible sera with eculizumab. The number in the upper right angle of each diagram indicates the time in days (d); 0d indicates the sample analyzed before any in vitro treatment. ECU: eculizumab. b Kinetics of C3 binding on PNH red cells from a series of PNH patients not on eculizumab after spontaneous complement activation in presence of eculizumab. The bar diagram shows the average (+SD) proportion of PNH (CD59-negative) red cells bound with C3 in a series of patients not on eculizumab after 3 and after 5 days of incubation at 37 °C in ABO-compatible sera with eculizumab. n: number of different patients studied at the indicated time points. Empty bars show the experiments without addition of MgCl2 whereas the filled bars show the experiments with the addition of MgCl2 (1.25 mM). C3 binding on PNH red cells increased significantly along the time (Wilcoxon signed paired test: P < 0.04 for the series without MgCl2 and P < 0.05 for the series with addition MgCl2). At both 3 and 5 days C3 binding of samples with MgCl2 was significantly higher than that of the same samples without MgCl2: P < 0.008, Wilcoxon signed paired test

Back to article page